000288715 001__ 288715
000288715 005__ 20240303010022.0
000288715 0247_ $$2doi$$a10.1080/16078454.2024.2320006
000288715 0247_ $$2pmid$$apmid:38407192
000288715 0247_ $$2ISSN$$a1024-5332
000288715 0247_ $$2ISSN$$a1024-5340
000288715 0247_ $$2ISSN$$a1607-8454
000288715 0247_ $$2altmetric$$aaltmetric:160127446
000288715 037__ $$aDKFZ-2024-00434
000288715 041__ $$aEnglish
000288715 082__ $$a610
000288715 1001_ $$00000-0001-7803-0814$$aSalwender, Hans$$b0
000288715 245__ $$aCytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial.
000288715 260__ $$aAbingdon, Oxon$$bTaylor & Francis$$c2024
000288715 3367_ $$2DRIVER$$aarticle
000288715 3367_ $$2DataCite$$aOutput Types/Journal article
000288715 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1709041733_14145
000288715 3367_ $$2BibTeX$$aARTICLE
000288715 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000288715 3367_ $$00$$2EndNote$$aJournal Article
000288715 520__ $$aThe seroprevalence of antibodies against Cytomegalovirus (CMV) is an established poor prognostic factor for patients receiving an allogeneic stem cell transplantation. However, the impact of CMV serology on outcome after autologous stem cell transplantation remains unknown.Here, we analyzed the CMV immunoglobulin (Ig) serology of 446 newly-diagnosed multiple myeloma (MM) patients of the GMMG-MM5 phase III trial with a median follow-up of 58 months.CMV IgG and IgM positivity was seen in 51% and 6% of the patients, respectively. In multivariate analysis CMV IgG and CMV IgM serology show an age-depending effect for PFS. We identified positive CMV IgG/positive CMV IgM serology as an age-depending beneficial factor on PFS.Younger patients with a positive CMV IgG/positive CMV IgM serology experienced a favorable effect on PFS, whereas a positive CMV IgG/positive CMV IgM serology at older age has a disadvantageous effect on PFS.
000288715 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000288715 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000288715 650_7 $$2Other$$aCMV
000288715 650_7 $$2Other$$aCMV IgM
000288715 650_7 $$2Other$$aCMV-Infection
000288715 650_7 $$2Other$$aGMMG-MM5 Phase III Trial
000288715 650_7 $$2Other$$aage-depending effect
000288715 650_7 $$2Other$$aautologous stem cell transplantation
000288715 650_7 $$2Other$$amaintenance therapy
000288715 650_7 $$2Other$$amultiple myeloma
000288715 650_7 $$0129L90A25N$$2NLM Chemicals$$acytomegalovirus-specific hyperimmune globulin
000288715 650_7 $$2NLM Chemicals$$aImmunoglobulins, Intravenous
000288715 650_7 $$2NLM Chemicals$$aAntibodies, Viral
000288715 650_7 $$2NLM Chemicals$$aImmunoglobulin G
000288715 650_7 $$2NLM Chemicals$$aImmunoglobulin M
000288715 650_2 $$2MeSH$$aHumans
000288715 650_2 $$2MeSH$$aCytomegalovirus
000288715 650_2 $$2MeSH$$aHematopoietic Stem Cell Transplantation
000288715 650_2 $$2MeSH$$aMultiple Myeloma: diagnosis
000288715 650_2 $$2MeSH$$aMultiple Myeloma: therapy
000288715 650_2 $$2MeSH$$aPrevalence
000288715 650_2 $$2MeSH$$aSeroepidemiologic Studies
000288715 650_2 $$2MeSH$$aTransplantation, Autologous
000288715 650_2 $$2MeSH$$aImmunoglobulins, Intravenous
000288715 650_2 $$2MeSH$$aAntibodies, Viral
000288715 650_2 $$2MeSH$$aImmunoglobulin G
000288715 650_2 $$2MeSH$$aCytomegalovirus Infections: epidemiology
000288715 650_2 $$2MeSH$$aImmunoglobulin M
000288715 7001_ $$aWeinhold, Niels$$b1
000288715 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b2$$udkfz
000288715 7001_ $$0P:(DE-He78)b97fc5666ea8f9db9ef499de6b2397cf$$aMiah, Kaya$$b3$$udkfz
000288715 7001_ $$aMerz, Maximilian$$b4
000288715 7001_ $$aHaenel, Mathias$$b5
000288715 7001_ $$aJehn, Christian$$b6
000288715 7001_ $$aMai, Elias$$b7
000288715 7001_ $$aMenis, Ekaterina$$b8
000288715 7001_ $$aBlau, Igor$$b9
000288715 7001_ $$aScheid, Christof$$b10
000288715 7001_ $$aHose, Dirk$$b11
000288715 7001_ $$aSeckinger, Anja$$b12
000288715 7001_ $$aLuntz, Steffen$$b13
000288715 7001_ $$aBesemer, Britta$$b14
000288715 7001_ $$aMunder, Markus$$b15
000288715 7001_ $$aBrossart, Peter$$b16
000288715 7001_ $$aGlass, Bertram$$b17
000288715 7001_ $$aLindemann, Hans-Walter$$b18
000288715 7001_ $$aWeisel, Katja$$b19
000288715 7001_ $$aHanoun, Christine$$b20
000288715 7001_ $$aSchnitzler, Paul$$b21
000288715 7001_ $$aKlemm, Sarah$$b22
000288715 7001_ $$aGoldschmidt, Hartmut$$b23
000288715 7001_ $$aRaab, Marc$$b24
000288715 7001_ $$aElmaagacli, Ahmet$$b25
000288715 773__ $$0PERI:(DE-600)2035573-7$$a10.1080/16078454.2024.2320006$$gVol. 29, no. 1, p. 2320006$$n1$$p2320006$$tHematology$$v29$$x1024-5332$$y2024
000288715 909CO $$ooai:inrepo02.dkfz.de:288715$$pVDB
000288715 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000288715 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b97fc5666ea8f9db9ef499de6b2397cf$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000288715 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000288715 9141_ $$y2024
000288715 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHEMATOLOGY : 2014
000288715 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000288715 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000288715 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000288715 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000288715 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000288715 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000288715 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000288715 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000288715 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000288715 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000288715 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-21T08:11:22Z
000288715 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-21T08:11:22Z
000288715 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Double anonymous peer review$$d2023-07-21T08:11:22Z
000288715 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000288715 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000288715 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000288715 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000288715 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000288715 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHEMATOLOGY : 2022$$d2023-10-24
000288715 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000288715 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000288715 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-24
000288715 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-24
000288715 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-24
000288715 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000288715 980__ $$ajournal
000288715 980__ $$aVDB
000288715 980__ $$aI:(DE-He78)C060-20160331
000288715 980__ $$aUNRESTRICTED